Precision Pharmacotherapy Enables Precision Medicine

Jeffrey R. Bishop, Vicki L. Ellingrod

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)985-987
Number of pages3
Issue number9
StatePublished - Sep 2017

Bibliographical note

Funding Information:
This evolution from pharmacogenomics to precision medicine has been driven by advancements in our knowledge of disease mechanisms that have improved treatments for complex illnesses. These advances have been supported by a general research-sharing infrastructure provided by the National Institutes of Health (NIH). In 2000, the NIH supported the creation of the Pharmacoge-nomics Knowledge Base (PharmGKB) and the Pharmacogenomics Research Network (PGRN), which currently still serves as a primary resource for pharmacogenomic information. In fact, the partnership between PharmGKB and the PGRN has resulted in the establishment of the Clinical Pharmacogenomics Implementation Consortium (CPIC), which provides clinical practice guidelines for the interpretation of pharmacogenomic results, as it recognized early that guidelines were needed to help clinicians make rational prescribing decisions based on pharmacogenomic information.5 Recently, work has described that one of

Cite this